BIAsp30 A 1 chieve Tehran 31 July 2015
|
|
- Chloe Watson
- 8 years ago
- Views:
Transcription
1 BIAsp30 A 1 chieve Tehran 31 July 2015
2 Beginning insulin with biphasic insulin aspart 30: experience from the A 1 chieve study Professor Philip Home Newcastle University
3 Presenter and sponsor duality of interest Duality of interest Philip Home, for himself or institutions with which he is associated, receives funding from all major insulin manufacturers including Novo Nordisk for his research, educational and advisory activities Role of sponsor Novo Nordisk, was involved in the design, data acquisition, and data analysis of the study, and funded the investigators to provide data from consented people with diabetes. Novo Nordisk is the developer and manufacturer of the insulins studied Acknowledgements We are grateful to all the investigators and people with diabetes who gave time and energy to this study
4 A 1 chieve biphasic aspart results: insulin naive Key messages In routine care, beginning biphasic insulin aspart 30 (BIAsp30) is associated with very good improvements in glucose control Such improvements are not associated with problems of weight gain or exacerbation of hypoglycaemia Health economic modelling, incorporating the findings and quality of life data, show very good cost-effectiveness
5 A 1 chieve biphasic aspart results: insulin naive Presentation structure and attributions Study design and rationale Population characteristics Results: biphasic insulin aspart 30 biomedical measures quality of life special groups Health economics Regional, other insulins, and predictor papers not included
6 A 1 chieve biphasic aspart results: insulin naive Presentation structure and attributions Study design and rationale Population characteristics Results: biphasic insulin aspart 30 biomedical measures quality All data of life are taken from special groups Health economics Home et al, Diabetes Res Clin Pract, 2011 (core findings) Shah et al, Diabetes Res Clin Pract, 2011 (QoL findings) Shah et al, Diabetes Tech Therapeutics, 2013 (BIAsp30 naive) Khamseh et al, Diabetes Ther, 2013 (older adults) Shafie et al, Diabetes Res Clin Pract, 2014 (health economics)
7 Why perform observational studies? Randomized controlled trials (RCTs) are performed in selected study populations well-motivated participants selected countries RCTs are intensive and closely monitored expensive to perform small populations Observational studies aim to characterize what happens in routine clinical care more typical populations wide geographical recruitment large numbers as less expensive per head
8 Why perform observational studies? Randomized controlled trials (RCTs) are performed in selected study populations Limitations of observational studies well-motivated participants selected countries Selection of investigators and sites RCTs are intensive will and vary closely by site monitored and region expensive Limited to perform therapy choice small populations Results are associative not causative Observational studies aim to characterize what happens in routine clinical care more typical populations wide geographical recruitment large numbers as less expensive per head
9 A 1 chieve study overview and design Observational study of people with T2DM (n=66 726) starting insulin analogues in routine clinical practice Global (non-western) recruitment 28 countries 3166 sites Non-interventional Insulin chosen by investigator n=1138 n= n=4039 n=3074 n= n= n= Other clinical care, measurements, and insulins provided as in routine clinical practice
10 A 1 chieve study overview and design Observational study of people with T2DM starting insulin analogues in routine clinical practice Insulin naïve or Insulin users Start a study insulin BIAsp30 Insulin detemir Insulin aspart BASELINE Week 0 INTERIM Week 12 FINAL Week 24
11 A 1 chieve study overview and design Observational study of people with T2DM starting insulin analogues in routine clinical practice Insulin naïve or Insulin users Start a study insulin BIAsp30 Insulin detemir Insulin aspart BASELINE Week 0 INTERIM Week 12 FINAL Week 24 Study objectives Primary: number of attributed adverse drug reactions Secondary: other safety and effectiveness measures Population (biphasic insulin aspart 30, insulin naive) Sex 58% male, age 53.0 (SD 11.5) yr, BMI (kg/m 2 ) 26.1 (4.2), duration of diabetes 6.2 (5.2) yr, time on oral agents 5.4 (4.9) yr
12 A 1 chieve: participant distribution by pre-study therapy and allocated insulin Insulin ± OGLD 32.8% Pre-study therapy No therapy 9.0% Basal+aspart 6.2% Study therapy Aspart 5.9% Others 3.2% OGLD alone 58.2% Detemir 23.3% Biphasic aspart % Insulin naïve to biphasic aspart 30: n= (41 %) OGLD, oral glucose-lowering drug
13 A 1 chieve: change in HbA 1c overall Pre-study therapy Global None OGLDs only Insulin Baseline: n: ΔHbA 1c (%) Data is change, Data is baseline change, to baseline 24 weeks. to 24 All weeks changes p<0.001 All changes p<0.001
14 A 1 chieve: change in HbA 1c overall and by pre-study therapy group Pre-study therapy Global None OGLDs only Insulin Baseline: n: ΔHbA 1c (%) OGLD, oral glucose-lowering drug Data is change, baseline to 24 weeks. All changes p<0.001
15 A 1 chieve: HbA 1c results for biphasic aspart 30 HbA 1c (%) HbA 1c (%) HbA 1c (%) insulin naïve insulin dose (U/day) 33 baseline 24 weeks 7.3
16 A 1 chieve: SMPG results for biphasic aspart 30 Plasma glucose (mmol/l) 15.0 HbA 1c (%) pre-breakfast insulin naïve post-breakfast 15.6 (281) Plasma glucose (mg/dl) ( 104) (200) baseline 4.0 ( 72) 7.1 (128) 24 weeks baseline 9.8 (176) 24 weeks
17 A 1 chieve: SMPG results for biphasic aspart 30 Plasma glucose (mmol/l) 15.0 HbA 1c (%) pre-breakfast insulin naïve post-breakfast 15.6 (281) Plasma glucose (mg/dl) ( 104) (200) baseline 4.0 ( 72) 7.1 (128) 24 weeks baseline 9.8 (176) 24 weeks
18 A 1 chieve: Hypoglycaemia with biphasic aspart 30 Events/ person-yr HbA 1c (%) insulin naïve Data collected in the last 4 weeks before visits HbA 1c (%) baseline 24 weeks
19 A 1 chieve: weight change with biphasic aspart 30 ΔWeight (kg) HbA 1c (%) insulin naïve HbA 1c (%) baseline 24 weeks
20 A 1 chieve: HbA 1c and hypoglycaemia according to age group with biphasic aspart 30 Age (years) 40 >40 65 >65 HbA 1c baseline (%) 9.6 (1.8) 9.5 (1.6) 9.5 (1.9) change (%-units) -2.4 (1.8) -2.1 (1.6) -2.2 (1.8) Hypoglycaemia people (%) people (%) event/person-year
21 A 1 chieve: change in EQ-5D visual analogue score biphasic aspart Best imaginable health (%) Worst imaginable health
22 A 1 chieve: change in EQ-5D visual analogue score biphasic aspart insulin naïve 24 weeks Baseline Best imaginable health (%) Worst imaginable health
23 A 1 chieve: change in EQ-5D visual analogue score components: biphasic aspart 100 Participants with 75 problem (%) 50 Mobility Self-care Usual Pain Anxiety activity discomfort depression 25 0 Baseline 24 weeks
24 A 1 chieve: lipid levels and systolic BP at baseline and 24 weeks on biphasic aspart Lipid levels (mmol/l) Baseline 24 weeks Systolic BP (mmhg) LDL cholesterol Triglyceride HDL cholesterol
25 A 1 chieve: health economic analysis for biphasic aspart 30 in insulin-naïve people Saudi Arabia India Indonesia N Africa 30-year ICER (cost per QALY gained) US dollar GDP fraction year ICER (cost per QALY gained) US dollar GDP fraction ICER, incremental cost-effectiveness ratio; QALY, quality adjusted life year Data analysis by CORE diabetes model Cost-effective USD <30 000, highly cost-effective < Cost-effective GDP fraction <3.0, highly cost-effective <1.0 (WHO)
26 A 1 chieve: overall summary for biphasic aspart 30 In insulin naïve people in poor blood glucose control starting biphasic insulin aspart : Blood glucose control measured as HbA 1c, FPG or PPPG improved markedly clinically & statistically significantly This was not accompanied by an increase in reported hypoglycaemia, or in body weight Useful and safe improvements in blood glucose control were seen in: all age groups and all global regions Systolic blood pressure and health-related quality of life were also improved to a clinically useful extent The intervention was highly cost-effective in a range of countries
27 A 1 chieve BIAsp 30: comment and interpretation The results suggest that in routine clinical practice biphasic insulin aspart 30 can deliver the gains seen in clinical trials The lack of weight gain despite marked improvement in HbA 1c, and the improvement in blood pressure, suggest that starting insulin analogues can be an opportunity for enhanced lifestyle behaviours The lack of increase in hypoglycaemia despite marked improvement in HbA 1c also suggests improved self-management The cost-effectiveness data suggests wide implementation is desirable
28 A 1 chieve BIAsp30: conclusion Globally, in routine clinical practice, starting biphasic insulin aspart is an opportunity, in insulin naïve people in poor metabolic control, to improve their cardiovascular risk profile and health-related quality of life without detriment to safety or excess cost
29 A 1 chieve BIAsp30: conclusion Globally, in routine clinical practice, starting biphasic insulin aspart is an opportunity, in insulin naïve people in poor metabolic control, to improve their cardiovascular risk profile and health-related quality of life without detriment to safety or excess cost Thank you for your attention, and to all the participants and investigators in Iran who contributed to the study
30 Thank you for your attention
31
diabetes research and clinical practice 101 (2013) 326 332
diabetes research and clinical practice 101 (2013) 326 332 The effectiveness and safety of beginning insulin aspart together with basal insulin in people with type 2 diabetes in non-western nations: Results
More informationInsulin detemir in the management of type 2 diabetes in non-western countries: Safety and effectiveness data from the A 1 chieve observational study,
Article in press DIABETES RESEARCH A ND CLINICAL PRACTICE xxx (2013) xxx xxx Insulin detemir in the management of type 2 diabetes in non-western countries: Safety and effectiveness data from the A 1 chieve
More informationA propensity score matched comparison of different insulin regimens 1 year after beginning insulin in people with type 2 diabetes
original article Diabetes, Obesity and Metabolism 15: 1120 1127, 2013. 2013 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. original article A propensity score matched
More informationINSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT
INSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT APIRADEE SRIWIJITKAMOL DIVISION OF ENDOCRINOLOGY AND METABOLISM DEPARTMENT OF MEDICINE FACULTY OF MEDICINE SIRIRAJ HOSPITOL QUESTION 1 1. ท านเคยเป นแพทย
More informationAre insulin analogs worth their cost in type 2 diabetes?
Keystone, Colorado 2012 Are insulin analogs worth their cost in type 2 diabetes? Dr. Amanda Adler Consultant Physician, Institute of Metabolic Sciences Addenbrooke s Hospital, Cambridge Chair, Technology
More informationThe first endoscopically-delivered device therapy for obese patients with type 2 diabetes
DIABETES WEIGHT ENDOBARRIER THERAPY The first endoscopically-delivered device therapy for obese patients with type 2 diabetes Restore the metabolic health of your patients with EndoBarrier Therapy. Dual
More informationImproving cardiometabolic health in Major Mental Illness
Improving cardiometabolic health in Major Mental Illness Dr. Adrian Heald Consultant in Endocrinology and Diabetes Leighton Hospital, Crewe and Macclesfield Research Fellow, Manchester University Metabolic
More informationInsulin degludec (Tresiba) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks
Background: Insulin degludec (Tresiba) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks Final Background and Scope November 19, 2015 The Centers for Disease Control
More informationWorkshop A Tara Kadis
Workshop A Tara Kadis Considerations/barriers in decision making about insulin verses GLP-1 use in people with type 2 diabetes Which Insulin regimes should we consider? Diabetes is a progressive multi-system
More informationSHORT CLINICAL GUIDELINE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SHORT CLINICAL GUIDELINE SCOPE 1 Guideline title Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes 1.1 Short title Type 2
More informationSponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,
More informationAdherence to insulin therapy at a tertiary care diabetes center in South India
Original Article: Adherence to insulin therapy at a tertiary care diabetes center in South India M.S. Raut, J. Balasubramanian, R.M. Anjana, R Unnikrishnan, *V. Mohan Abstract To assess patient adherence
More information嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯
The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized
More informationADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril,
More informationDiabetes Mellitus 1. Chapter 43. Diabetes Mellitus, Self-Assessment Questions
Diabetes Mellitus 1 Chapter 43. Diabetes Mellitus, Self-Assessment Questions 1. A 46-year-old man presents for his annual physical. He states that he has been going to the bathroom more frequently than
More informationStatins and Risk for Diabetes Mellitus. Background
Statins and Risk for Diabetes Mellitus Kevin C. Maki, PhD, FNLA Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL 1 Background In 2012 the US Food and Drug Administration
More informationThe Economic Impact and Cost-Effectiveness of Glucose Monitoring
The Economic Impact and Cost-Effectiveness of Glucose Monitoring William H. Herman, MD, MPH Stefan S. Fajans/GlaxoSmithKline Professor of Diabetes Professor of Internal Medicine and Epidemiology University
More informationManaging diabetes in the post-guideline world. Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ)
Managing diabetes in the post-guideline world Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ) Overview Pathogenesis of T2DM Aims of treatment The place of glycaemic control Strategies to improve glycaemic
More informationShanmugasundar G., Anil Bhansali, Rama Walia, Pinaki Dutta & Vimal Upreti
Indian J Med Res 135, January 2012, pp 78-83 Comparison of thrice daily biphasic human insulin (30/70) versus basal detemir & bolus aspart in patients with poorly controlled type 2 diabetes mellitus A
More informationIMPROVED METABOLIC CONTROL WITH A FAVORABLE WEIGHT PROFILE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH INSULIN GLARGINE (LANTUS ) IN CLINICAL
464 IMPROVED METABOLIC CONTROL WITH A FAVORABLE WEIGHT PROFILE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH INSULIN GLARGINE (LANTUS ) IN CLINICAL PRACTICE STEPHAN A SCHREIBER AND ANIKA RUßMAN ABSTRACT
More informationLeon Litwak 1*, Su-Yen Goh 2, Zanariah Hussein 3, Rachid Malek 4, Vinay Prusty 5 and Mohammad E Khamseh 6
Litwak et al. Diabetology & Metabolic Syndrome 2013, 5:57 DIABETOLOGY & METABOLIC SYNDROME RESEARCH Open Access Prevalence of diabetes complications in people with type 2 diabetes mellitus and its association
More informationInsulin or GLP1 How to make this choice in Practice. Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust
Insulin or GLP1 How to make this choice in Practice Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust Workshop Over View Considerations/barriers to treatments in type 2
More informationGuidelines for the management of hypertension in patients with diabetes mellitus
Guidelines for the management of hypertension in patients with diabetes mellitus Quick reference guide In the Eastern Mediterranean Region, there has been a rapid increase in the incidence of diabetes
More informationLiraglutide for the treatment of type 2 diabetes
DOI: 10.3310/hta15suppl1/09 Health Technology Assessment 2011; Vol. 15: Suppl. 1 77 Liraglutide for the treatment of type 2 diabetes D Shyangdan, 1 * E Cummins, 2 P Royle 1 and N Waugh 1 1 Department of
More informationInitiating & titrating insulin & switching in General Practice Workshop 1
Initiating & titrating insulin & switching in General Practice Workshop 1 Workshop goal To make participants comfortable in the timely initiation and titration of insulin Progression of Type 2 Diabetes
More informationInsulin Analogues versus Pump Therapy in Type 2 Diabetes: Benefits from Pump Therapy
Insulin Analogues versus Pump Therapy in Type 2 Diabetes: Benefits from Pump Therapy Eric RENARD, MD, PhD Endocrinology Dept, Lapeyronie Hospital Montpellier, France e-renard@chu-montpellier.fr Type 2
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PC - Apidra, Levemir Therapeutic Class: Hormones and Synthetic Substitutes Therapeutic Sub-Class: Antidiabetic Agents Client: CA, CO, NV, OK, OR, WA and AZ Approval
More informationSummary ID# 13614. Clinical Study Summary: Study F3Z-JE-PV06
CT Registry ID# Page 1 Summary ID# 13614 Clinical Study Summary: Study F3Z-JE-PV06 INSIGHTS; INSulin-changing study Intending to Gain patients insights into insulin treatment with patient-reported Health
More informationGlobal Guideline for Type 2 Diabetes
INTERNATIONAL DIABETES FEDERATION, 2005 Clinical Guidelines Task Force Global Guideline for Type 2 Diabetes Chapter 10: Glucose control: insulin therapy Copyright All rights reserved. No part of this publication
More informationClinical Research on Lifestyle Interventions to Treat Obesity and Asthma in Primary Care Jun Ma, M.D., Ph.D.
Clinical Research on Lifestyle Interventions to Treat Obesity and Asthma in Primary Care Jun Ma, M.D., Ph.D. Associate Investigator Palo Alto Medical Foundation Research Institute Consulting Assistant
More informationMain Effect of Screening for Coronary Artery Disease Using CT
Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,
More informationDiabetes: When To Treat With Insulin and Treatment Goals
Diabetes: When To Treat With Insulin and Treatment Goals Lanita. S. White, Pharm.D. Director, UAMS 12 th Street Health and Wellness Center Assistant Professor of Pharmacy Practice, UAMS College of Pharmacy
More informationHow To Treat Dyslipidemia
An International Atherosclerosis Society Position Paper: Global Recommendations for the Management of Dyslipidemia Introduction Executive Summary The International Atherosclerosis Society (IAS) here updates
More informationType 2 diabetes mellitus
Type 2 diabetes mellitus CLINICAL PRACTICE Management Guidelines for initiating insulin therapy BACKGROUND Insulin is often indicated for patients with suboptimally controlled type 2 diabetes mellitus,
More informationThe Arguments: T2DM - tremendous economic burden globally Lifestyle / Pharm Rx:
James Cromie The Arguments: T2DM - tremendous economic burden globally Lifestyle / Pharm Rx: INEFFECTIVE and UNSUSTAINED Bariatric surgery is an Effective and Durable treatment option Well established
More informationJill Malcolm, Karen Moir
Evaluation of Fife- DICE: Type 2 diabetes insulin conversion Article points 1. Fife-DICE is an insulin conversion group education programme. 2. People with greater than 7.5% on maximum oral therapy are
More informationHigh Blood Cholesterol
National Cholesterol Education Program ATP III Guidelines At-A-Glance Quick Desk Reference 1 Step 1 2 Step 2 3 Step 3 Determine lipoprotein levels obtain complete lipoprotein profile after 9- to 12-hour
More informationOverview and update of modern type 2 Diabetes philosophy and management. Dr Steve Stanaway Consultant Endocrinologist BCU
Overview and update of modern type 2 Diabetes philosophy and management Dr Steve Stanaway Consultant Endocrinologist BCU Diabetes economics 2009: 2.6M adults with DM in UK (90% type 2) 2025: est. > 4M
More informationTYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.
TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION Robert Dobbins, M.D. Ph.D. Learning Objectives Recognize current trends in the prevalence of type 2 diabetes. Learn differences between type 1 and type
More informationAccountable Care Project EMR Reporting Guide January 6, 2014
Accountable Care Project EMR Reporting Guide January 6, 2014 Web Reporting System The system can be accessed at http://www.nhaccountablecare.org. You will need the ID and password assigned to you by NHIHPP
More informationInvestigation of the effect of isomaltulose (PalatinoseTM) on metabolic parameters in subjects with Type 2 Diabetes.
PLEASE NOTE: This trial has been registered retrospectively. Trial Description Title Investigation of the effect of isomaltulose (PalatinoseTM) on metabolic parameters in subjects with Type 2 Diabetes.
More informationAbstract presented at 2009 American Association of Diabetes Educators annual meeting
Title Utilizing Diabetes Conversation Maps as an Interactive Reinforcement Mechanism South University School of Pharmacy and Tuttle Army Health Clinic Use Conversation Maps as an interactive reinforcement
More informationMany patients with type 2 diabetes will ultimately need
SUPPLEMENT TO JAPI april 2011 VOL. 59 17 Insulin Initiation and Intensification: Insights from New Studies Ajay Kumar 1, Sanjay Kalra 2 Abstract Tight glycemic control is central to reducing the risk of
More informationJournal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators
Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Shaikha Al Naimi Doctor of Pharmacy Student College of Pharmacy Qatar University
More informationType 2 Diabetes workshop notes
Group 1 notes Abi / Nicole Type 2 Diabetes workshop notes 4.1 Population The group discussed the following sub groups that may need addressing: Men-as they tend to die earlier compared with women, their
More informationInsulin switch & Algorithms Rotorua GP CME June 2011. Kingsley Nirmalaraj FRACP Endocrinologist BOPDHB
Insulin switch & Algorithms Rotorua GP CME June 2011 Kingsley Nirmalaraj FRACP Endocrinologist BOPDHB Goal of workshop Insulin switching make the necessary move Ensure participants are confident with Recognising
More informationMANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING
More informationMaking the case for insulin pump therapy
T Ulahannan*, NN Myint, KF Lonnen Introduction Previously used economic models of continuous subcutaneous insulin infusion (CSII/insulin pump therapy) projected long-term costs and outcomes compared to
More informationProtein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075
Title: Protein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075 Investigator: Institution: Gail Gates, PhD, RD/LD Oklahoma State University Date
More informationVascular Risk Reduction: Addressing Vascular Risk
Vascular Risk Reduction: Addressing Vascular Risk Vascular Risk Reduction (VRR) Welcome! Presentation & Activities Focus: Managing known risk factors for vascular disease. Engage, collaborate and have
More informationNCT00272090. sanofi-aventis HOE901_3507. insulin glargine
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationEvaluation of a Nurse-Care Management System to Improve Outcomes in Patients With Complicated Diabetes
Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Evaluation of a Nurse-Care Management System to Improve Outcomes in Patients With Complicated Diabetes C. BARR TAYLOR, MD
More informationThe basal plus strategy. Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE
The basal plus strategy Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE ADA/EASD guidelines recommend use of basal insulin as early as the second step
More informationAntiretroviral treatment is Associated with increased Arterial Stiffness in Sub- Saharan African HIV-1 Infected Patients: A cross- Sectional Study
Antiretroviral treatment is Associated with increased Arterial Stiffness in Sub- Saharan African HIV-1 Infected Patients: A cross- Sectional Study Titus F. Msoka Supervisors Marceline van Furth Yvo Smulders
More informationIntensive Insulin Therapy in Diabetes Management
Intensive Insulin Therapy in Diabetes Management Lillian F. Lien, MD Medical Director, Duke Inpatient Diabetes Management Assistant Professor of Medicine Division of Endocrinology, Metabolism, & Nutrition
More informationSanofi Reports Positive Phase 3 Results for Toujeo (insulin glargine [rdna origin] injection, 300 U/mL)
PRESS RELEASE Sanofi Reports Positive Phase 3 Results for Toujeo (insulin glargine [rdna origin] injection, 300 U/mL) Meta-analysis of three late-stage trials in people with type 2 diabetes shows decreases
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines) Authors: Dr. M. Love, Kathy Harrigan Reviewers:
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationReversing type 2 diabetes: pancreas composition and function during return to normal glucose tolerance
Reversing type 2 diabetes: pancreas composition and function during return to normal glucose tolerance Dr Sarah Steven Clinical Research Fellow to Professor Roy Taylor Observations from bariatric surgery
More informationHôpitaux Universitaires de Genève Lipides, métabolisme des hydrates de carbonne et maladies cardio-vasculaires
Hôpitaux Universitaires de Genève Lipides, métabolisme des hydrates de carbonne et maladies cardio-vasculaires Prof. J. Philippe Effect of estrogens on glucose metabolism : Fasting Glucose, HbA1c and C-Peptide
More informationDCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study
DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study National Diabetes Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What
More informationAn important first step in identifying those at risk for Cardiovascular disease The Accutrend Plus system: from the makers of the ACCU-CHEK and
An important first step in identifying those at risk for Cardiovascular disease The Accutrend Plus system: from the makers of the ACCU-CHEK and CoaguChek systems Cardiovascular disease: the #1 killer in
More informationSystolic Blood Pressure Intervention Trial (SPRINT) Principal Results
Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Paul K. Whelton, MB, MD, MSc Chair, SPRINT Steering Committee Tulane University School of Public Health and Tropical Medicine, and
More informationDiabetes and Obesity in Children. Janie Berquist, RN, BSN, MPH, CDE Children s Mercy Hospitals and Clinics Kansas City, MO
Diabetes and Obesity in Children Janie Berquist, RN, BSN, MPH, CDE Children s Mercy Hospitals and Clinics Kansas City, MO Diabetes and Obesity in Children What is Diabetes? How are Diabetes and Obesity
More informationEfficacy and Safety of Insulin Aspart in Patients with Type 1 Diabetes Mellitus
Clin Pediatr Endocrinol 2002; 11(2), 87-92 Copyright 2002 by The Japanese Society for Pediatric Endocrinology Original Efficacy and Safety of Insulin Aspart in Patients with Type 1 Diabetes Mellitus Toshikazu
More informationEfficacy, safety and preference study of a insulin pen PDS290 vs. a Novo Nordisk marketed insulin pen in diabetics
Efficacy, safety and preference study of a insulin pen PDS290 vs. a Novo Nordisk marketed insulin pen in diabetics This trial is conducted in the United States of America (USA). The aim of this clinical
More informationScottish Medicines Consortium
Scottish Medicines Consortium insulin glulisine for subcutaneous injection 100 units/ml (Apidra ) No. (298/06) Sanofi Aventis 4 August 2006 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationPresent and Future of Insulin Therapy: Research Rationale for New Insulins
Present and Future of Insulin Therapy: Research Rationale for New Insulins Current insulin analogues represent an important advance over human insulins, but clinically important limitations of these agents
More information3 WORKSHOP CONGIUNTO SICOb SID SIO 7 MARZO 2014 L integrazione tra terapia medica e chirurgica nel trattamento del paziente obeso diabetico
3 WORKSHOP CONGIUNTO SICOb SID SIO 7 MARZO 2014 L integrazione tra terapia medica e chirurgica nel trattamento del paziente obeso diabetico Recidive del diabete dopo terapia chirurgica La quantificazione
More informationShort-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis
ORIGINAL ARTICLE doi: 10.1111/j.1463-1326.2008.00934.x Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis E. Mannucci, M. Monami and N. Marchionni Department of
More informationObesity in the United States Workforce. Findings from the National Health and Nutrition Examination Surveys (NHANES) III and 1999-2000
P F I Z E R F A C T S Obesity in the United States Workforce Findings from the National Health and Nutrition Examination Surveys (NHANES) III and 1999-2000 p p Obesity in The United States Workforce One
More informationJNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates. January 30, 2014
JNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates January 30, 2014 GOALS Review key recommendations from recently published guidelines on blood pressure and cholesterol management Discuss
More informationMetabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007
Metabolic Syndrome Overview: Easy Living, Bitter Harvest Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007 Evolution of Metabolic Syndrome 1923: Kylin describes clustering
More informationDiabetes Subcommittee of PTAC meeting. held 18 June 2008. (minutes for web publishing)
Diabetes Subcommittee of PTAC meeting held 18 June 2008 (minutes for web publishing) Diabetes Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics
More informationAn Interprofessional Approach to Diabetes Management
Disclosures An Interprofessional Approach to Diabetes Management Principal in DiabetesReframed, LLC. Inventor of U.S. Provisional Patent Application No. 61/585,483 METHODS OF USING A DIABETES CROSS- DISCIPLINARY
More informationTYPE 2 DIABETES SEQUENTIAL INSULIN STRATEGIES
TYPE 2 DIABETES SEQUENTIAL INSULIN STRATEGIES Non-insulin regimes Basal insulin only (usually with oral agents) Number of injections 1 Regimen complexity Low Basal insulin +1 meal-time rapidacting insulin
More informationType 2 Diabetes - Pros and Cons of Insulin Administration
Do we need alternative routes of insulin administration (inhaled insulin) in Type 2 diabetes? Cons: Suad Efendic Karolinska Institutet, Sweden The Diabetes Management Situation Today Diabetes is a growing
More informationBritni Hebert, MD PGY-1
Britni Hebert, MD PGY-1 Importance of Diabetes treatment Types of treatment Comparison of treatment/article Review Summary Example cases 1 out of 13 Americans have diabetes Complications include blindness,
More informationHDL Cholesterol Subfractions and the Effect of Testosterone Replacement in Hypogonadism
HDL Cholesterol Subfractions and the Effect of Testosterone Replacement in Hypogonadism E. Bolu 1, A. Sonmez 1, S. Tapan 2, A. Taslipinar 1, A. Aydogdu 1, C. Meric 1, Y. Basaran 1, G. Uckaya 1, M. Serdar
More informationBarriers to Healthcare Services for People with Mental Disorders. Cardiovascular disorders and diabetes in people with severe mental illness
Barriers to Healthcare Services for People with Mental Disorders Cardiovascular disorders and diabetes in people with severe mental illness Dr. med. J. Cordes LVR- Klinikum Düsseldorf Kliniken der Heinrich-Heine-Universität
More informationAlgorithms for Glycemic Management of Type 2 Diabetes
KENTUCKY DIABETES NETWORK, INC. Algorithms for Glycemic Management of Type 2 Diabetes The Diabetes Care Algorithms for Type 2 Diabetes included within this document are taken from the American Association
More informationGUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY*
71 GUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY* Ryuichi KIKKAWA** Asian Med. J. 44(2): 71 75, 2001 Abstract: Diabetic nephropathy is the most devastating complication of diabetes and is now the
More informationMY TYPE 2 DIABETES NUMBERS
BLOOD SUGAR MANAGEMENT GUIDE MY TYPE 2 DIABETES NUMBERS Understanding and Tracking the ABCs of Type 2 Diabetes 1 BLOOD MY TYPE SUGAR 2 DIABETES MANAGEMENT ABC NUMBERS GUIDE When you have type 2 diabetes,
More informationTherapy Insulin Practical guide to Health Care Providers Quick Reference F Diabetes Mellitus in Type 2
Ministry of Health, Malaysia 2010 First published March 2011 Perkhidmatan Diabetes dan Endokrinologi Kementerian Kesihatan Malaysia Practical guide to Insulin Therapy in Type 2 Diabetes Mellitus Quick
More informationDiabetes Prevention in Latinos
Diabetes Prevention in Latinos Matthew O Brien, MD, MSc Assistant Professor of Medicine and Public Health Northwestern Feinberg School of Medicine Institute for Public Health and Medicine October 17, 2013
More informationHypertension and Diabetes Status. 2011 Bangladesh Demographic and Health Survey
Hypertension and Diabetes Status 2011 Bangladesh Demographic and Health Survey Methodology and Sampling Total 18,000 households were selected nationwide (207 in urban and 393 in rural areas) One-third
More informationI have diabetes. In case of emergency, please call: Healthcare Provider s Name. Name. Telephone. Address. Hospital. City. Pharmacy.
Self-Care Diary Name Address City Healthcare Provider s Name Hospital State ZIP I have diabetes. In case of emergency, please call: Name Pharmacy Diabetes Educator s Name Address 1 Small Steps to Managing
More informationCHAPTER V DISCUSSION. normal life provided they keep their diabetes under control. Life style modifications
CHAPTER V DISCUSSION Background Diabetes mellitus is a chronic condition but people with diabetes can lead a normal life provided they keep their diabetes under control. Life style modifications (LSM)
More informationBaskets of Care Diabetes Subcommittee
Baskets of Care Diabetes Subcommittee Disclaimer: This background information is not intended to be a comprehensive scientific discussion of the topic, but rather an attempt to provide a baseline level
More informationSponsor / Company: Sanofi Drug substance(s): HOE901 (insulin glargine)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationPopulation Health Management Program
Population Health Management Program Program (formerly Disease Management) is dedicated to improving our members health and quality of life. Our Population Health Management Programs aim to improve care
More informationCOST ANALYSIS OF ANTIDIABETIC DRUGS FOR DIABETES MELLITUS OUTPATIENT IN KODYA YOGYAKARTA HOSPITAL
Malaysian Journal of Pharmaceutical Sciences, Vol. 5, No. 1, 19 23 (2007) COST ANALYSIS OF ANTIDIABETIC DRUGS FOR DIABETES MELLITUS OUTPATIENT IN KODYA YOGYAKARTA HOSPITAL TRI MURTI ANDAYANI* AND IKE IMANINGSIH
More informationStarting patients on the V-Go Disposable Insulin Delivery Device
Starting patients on the V-Go Disposable Insulin Delivery Device A simple guide for your practice For adult patients with Type 2 diabetes on basal insulin who need to take the next step Identify appropriate
More informationThe Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery
The Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery Michael E. Farkouh, MD, MSc Peter Munk Chair in Multinational Clinical Trials Director, Heart and Stroke
More informationLinköping University Post Print
Linköping University Post Print Can diabetes medication be reduced in elderly patients?: An observational study of diabetes drug withdrawal in nursing home patients with tight glycaemic control Peter Sjöblom,
More informationTechnology Assessment
Technology Assessment Lifestyle Interventions for Four Conditions: Type 2 Diabetes, Metabolic Syndrome, Breast Cancer, and Prostate Cancer Technology Assessment Program Prepared for: Agency for Healthcare
More informationGetting Off the Chronic Disease Merry-Go-Round: What s the Weight of the Research?
Getting Off the Chronic Disease Merry-Go-Round: What s the Weight of the Research? Jody Dushay, MD MMSc Beth Israel Deaconess Medical Center Boston, MA Session 445 No disclosures Disclosure Jody Dushay,
More informationA Simplified Approach to Initiating Insulin. 4. Not meeting glycemic goals with oral hypoglycemic agents or
A Simplified Approach to Initiating Insulin When to Start Insulin: 1. Fasting plasma glucose (FPG) levels >250 mg/dl or 2. Glycated hemoglobin (A1C) >10% or 3. Random plasma glucose consistently >300 mg/dl
More informationPresented By: Dr. Nadira Husein
Presented By: Dr. Nadira Husein I have no conflict of interest Disclosures I have received honoraria/educational grants from the following: Novo Nordisk, Eli Lilly, sanofi-aventis, Novartis, Astra Zeneca,
More informationPersonalized Therapy Algorithms for Type 2 Diabetes: A Phenotypization-based Approach
Personalized Therapy Algorithms for Type 2 Diabetes: A Phenotypization-based Approach Riccardo Candido on behalf of the Personalized Therapy AMD Study Group Diabetes Canter A.S.S. 1 Triestina, Italy BACKGROUND
More information